Table 3 Toxicity per patient (WHO grades) during the whole trial
From: Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study
Toxicity | Per patient (89) | Per cycle (487) | ||||
|---|---|---|---|---|---|---|
Grade 1–2 | Grade 3 | Grade 4 | Grade 1–2 | Grade 3 | Grade 4 | |
Anaemia | 24 (27%) | 5 (6%) | 60 (12%) | 7 (1%) | ||
Thrombocytopenia | 3 (3%) | 3 (1%) | ||||
Nausea/vomiting | 59 (66%) | 3 (3%) | 1 (1%) | 184 (38%) | 10 (2%) | 3 (1%) |
Diarrhoea | 32 (36%) | 10 (11%) | 3 (3%) | 94 (19%) | 7 (1%) | 6 (1%) |
Stomatitis | 6 (7%) | 2 (2%) | 8 (2%) | 2 (1%) | ||
Transaminases | 26 (29%) | 4 (4%) | 2 (2%) | 73 (15%) | 7 (1%) | 2 (1%) |
Asthenia | 27 (30%) | 3 (3%) | 109 (22%) | 3 (1%) | ||
Alopecia | 31 (35%) | 6 (7%) | 3 (3%) | 99 (20%) | 14 (3%) | 16 (3%) |
Cholinergic syndrome | 20 (22%) | 44 (9%) | ||||
